Judith Regensteiner
Concepts (532)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intermittent Claudication | 46 | 2022 | 122 | 4.830 |
Why?
| | Diabetes Mellitus, Type 2 | 55 | 2025 | 2588 | 4.300 |
Why?
| | Sex Characteristics | 18 | 2024 | 782 | 3.180 |
Why?
| | Peripheral Arterial Disease | 24 | 2022 | 507 | 3.120 |
Why?
| | Exercise | 47 | 2024 | 2198 | 2.980 |
Why?
| | Exercise Therapy | 31 | 2022 | 475 | 2.720 |
Why?
| | Peripheral Vascular Diseases | 25 | 2011 | 104 | 2.420 |
Why?
| | Sex Factors | 20 | 2024 | 2105 | 2.160 |
Why?
| | Oxygen Consumption | 33 | 2021 | 718 | 2.020 |
Why?
| | Cardiovascular Diseases | 23 | 2024 | 2187 | 1.880 |
Why?
| | Walking | 23 | 2022 | 542 | 1.830 |
Why?
| | Diabetes Mellitus | 18 | 2024 | 1097 | 1.780 |
Why?
| | Women's Health | 10 | 2024 | 314 | 1.740 |
Why?
| | Biomedical Research | 8 | 2024 | 717 | 1.370 |
Why?
| | Exercise Test | 38 | 2019 | 630 | 1.350 |
Why?
| | Cardiology | 6 | 2023 | 362 | 1.100 |
Why?
| | Exercise Tolerance | 15 | 2024 | 283 | 1.100 |
Why?
| | American Heart Association | 10 | 2019 | 358 | 1.070 |
Why?
| | Quality of Life | 18 | 2019 | 3204 | 0.990 |
Why?
| | Leg | 13 | 2021 | 242 | 0.980 |
Why?
| | Research Personnel | 5 | 2024 | 184 | 0.980 |
Why?
| | Humans | 185 | 2025 | 145475 | 0.870 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2024 | 81 | 0.830 |
Why?
| | Mentoring | 3 | 2022 | 165 | 0.830 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 208 | 0.800 |
Why?
| | Diabetic Angiopathies | 6 | 2017 | 264 | 0.800 |
Why?
| | Vascular Stiffness | 3 | 2023 | 486 | 0.790 |
Why?
| | Male | 104 | 2025 | 72843 | 0.760 |
Why?
| | Female | 108 | 2025 | 78845 | 0.760 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2024 | 443 | 0.740 |
Why?
| | Muscle, Skeletal | 14 | 2024 | 1789 | 0.740 |
Why?
| | Cardiovascular System | 5 | 2023 | 138 | 0.730 |
Why?
| | Community Health Services | 2 | 2015 | 231 | 0.730 |
Why?
| | Diabetic Cardiomyopathies | 3 | 2016 | 34 | 0.720 |
Why?
| | Education, Medical | 3 | 2020 | 275 | 0.700 |
Why?
| | Periodicals as Topic | 1 | 2024 | 209 | 0.700 |
Why?
| | Insulin Resistance | 12 | 2024 | 1244 | 0.660 |
Why?
| | Cardiorespiratory Fitness | 3 | 2025 | 74 | 0.640 |
Why?
| | Lower Extremity | 9 | 2019 | 445 | 0.640 |
Why?
| | Interdisciplinary Research | 1 | 2020 | 26 | 0.620 |
Why?
| | Arterial Occlusive Diseases | 7 | 2015 | 90 | 0.620 |
Why?
| | Sitagliptin Phosphate | 1 | 2019 | 31 | 0.590 |
Why?
| | Endothelium, Vascular | 6 | 2021 | 956 | 0.580 |
Why?
| | Middle Aged | 74 | 2025 | 36215 | 0.580 |
Why?
| | Obesity | 19 | 2023 | 3116 | 0.580 |
Why?
| | Aged | 57 | 2024 | 26153 | 0.570 |
Why?
| | Diastole | 1 | 2019 | 146 | 0.570 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 46 | 0.570 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2025 | 394 | 0.560 |
Why?
| | Surveys and Questionnaires | 23 | 2018 | 6066 | 0.540 |
Why?
| | Physical Fitness | 9 | 2016 | 207 | 0.540 |
Why?
| | Gender Identity | 1 | 2019 | 128 | 0.540 |
Why?
| | United States | 37 | 2024 | 16098 | 0.520 |
Why?
| | Hypertension | 6 | 2022 | 1273 | 0.510 |
Why?
| | Brachial Artery | 6 | 2015 | 208 | 0.510 |
Why?
| | Metabolomics | 2 | 2020 | 732 | 0.510 |
Why?
| | Hypoglycemic Agents | 9 | 2021 | 1399 | 0.510 |
Why?
| | Physical Exertion | 7 | 2009 | 205 | 0.500 |
Why?
| | Mitochondria, Muscle | 4 | 2024 | 120 | 0.500 |
Why?
| | Health Status | 4 | 2020 | 832 | 0.500 |
Why?
| | Blood Pressure | 12 | 2021 | 1779 | 0.500 |
Why?
| | Venoms | 1 | 2016 | 22 | 0.490 |
Why?
| | Vasodilator Agents | 4 | 2010 | 330 | 0.480 |
Why?
| | Curriculum | 2 | 2020 | 1070 | 0.470 |
Why?
| | Biomarkers | 6 | 2024 | 4295 | 0.450 |
Why?
| | Research Design | 5 | 2024 | 1137 | 0.430 |
Why?
| | Cardiac Rehabilitation | 3 | 2019 | 46 | 0.430 |
Why?
| | Life Style | 9 | 2018 | 485 | 0.420 |
Why?
| | National Institutes of Health (U.S.) | 4 | 2023 | 147 | 0.410 |
Why?
| | Arteriosclerosis | 5 | 2002 | 83 | 0.410 |
Why?
| | Physicians | 5 | 2024 | 955 | 0.390 |
Why?
| | Faculty, Medical | 6 | 2024 | 303 | 0.380 |
Why?
| | Sleep | 1 | 2020 | 888 | 0.380 |
Why?
| | Home Care Services | 4 | 2019 | 284 | 0.370 |
Why?
| | Microcirculation | 4 | 2017 | 142 | 0.370 |
Why?
| | Diabetes Mellitus, Type 1 | 9 | 2024 | 3922 | 0.360 |
Why?
| | Risk Factors | 29 | 2022 | 10885 | 0.360 |
Why?
| | Advisory Committees | 5 | 2019 | 229 | 0.360 |
Why?
| | Mentors | 4 | 2022 | 217 | 0.360 |
Why?
| | Overweight | 7 | 2025 | 614 | 0.350 |
Why?
| | Blood Flow Velocity | 4 | 2009 | 421 | 0.350 |
Why?
| | Longevity | 3 | 2024 | 178 | 0.350 |
Why?
| | Adult | 41 | 2025 | 40777 | 0.320 |
Why?
| | Peptides | 1 | 2016 | 998 | 0.320 |
Why?
| | Disability Evaluation | 2 | 2011 | 310 | 0.320 |
Why?
| | Ankle | 3 | 2008 | 64 | 0.320 |
Why?
| | Weight Loss | 6 | 2016 | 858 | 0.310 |
Why?
| | Gait | 2 | 2006 | 312 | 0.300 |
Why?
| | Treatment Outcome | 24 | 2022 | 11772 | 0.300 |
Why?
| | Regional Blood Flow | 11 | 2020 | 514 | 0.290 |
Why?
| | Tetrazoles | 3 | 2006 | 50 | 0.290 |
Why?
| | Cardiac Output, Low | 1 | 2009 | 53 | 0.290 |
Why?
| | Research Support as Topic | 2 | 2020 | 80 | 0.280 |
Why?
| | Thiazolidinediones | 3 | 2010 | 139 | 0.280 |
Why?
| | Physical Endurance | 3 | 2011 | 279 | 0.280 |
Why?
| | Double-Blind Method | 8 | 2019 | 2062 | 0.270 |
Why?
| | Ventricular Function, Left | 2 | 2025 | 542 | 0.270 |
Why?
| | Oxygen | 4 | 2018 | 978 | 0.270 |
Why?
| | Recovery of Function | 9 | 2019 | 716 | 0.270 |
Why?
| | Cost of Illness | 3 | 2018 | 324 | 0.270 |
Why?
| | Fear | 1 | 2011 | 368 | 0.260 |
Why?
| | Oxidative Phosphorylation | 2 | 2019 | 209 | 0.260 |
Why?
| | Glucagon-Like Peptide 1 | 2 | 2020 | 149 | 0.250 |
Why?
| | Hematologic Agents | 1 | 2006 | 3 | 0.250 |
Why?
| | Follow-Up Studies | 9 | 2024 | 5423 | 0.250 |
Why?
| | Activities of Daily Living | 5 | 2021 | 444 | 0.240 |
Why?
| | Perception | 1 | 2009 | 378 | 0.240 |
Why?
| | Blood Glucose | 10 | 2024 | 2341 | 0.240 |
Why?
| | Stents | 6 | 2015 | 564 | 0.240 |
Why?
| | Medicare | 2 | 2022 | 903 | 0.230 |
Why?
| | Disease Management | 4 | 2017 | 653 | 0.230 |
Why?
| | Motor Activity | 5 | 2012 | 718 | 0.230 |
Why?
| | Myocardial Perfusion Imaging | 1 | 2025 | 50 | 0.230 |
Why?
| | Foundations | 2 | 2018 | 27 | 0.220 |
Why?
| | Vascular Diseases | 4 | 2000 | 252 | 0.220 |
Why?
| | Caregivers | 3 | 2024 | 1073 | 0.220 |
Why?
| | Predictive Value of Tests | 6 | 2025 | 2121 | 0.220 |
Why?
| | Pharmacovigilance | 1 | 2024 | 24 | 0.220 |
Why?
| | Interdisciplinary Studies | 2 | 2017 | 30 | 0.220 |
Why?
| | Vascular Surgical Procedures | 5 | 2009 | 343 | 0.210 |
Why?
| | Echocardiography | 4 | 2018 | 647 | 0.210 |
Why?
| | Troponin | 1 | 2024 | 50 | 0.210 |
Why?
| | Societies, Medical | 3 | 2017 | 899 | 0.210 |
Why?
| | Feasibility Studies | 2 | 2022 | 1111 | 0.210 |
Why?
| | Vasodilation | 3 | 2015 | 521 | 0.210 |
Why?
| | Troponin T | 1 | 2024 | 63 | 0.210 |
Why?
| | Respiration | 3 | 1990 | 206 | 0.210 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2025 | 214 | 0.210 |
Why?
| | Troponin I | 1 | 2024 | 73 | 0.200 |
Why?
| | Heart Rate | 6 | 2015 | 855 | 0.200 |
Why?
| | Fibrinolysis | 2 | 2003 | 164 | 0.200 |
Why?
| | Kinetics | 5 | 2015 | 1567 | 0.200 |
Why?
| | Insulin | 5 | 2020 | 2512 | 0.200 |
Why?
| | Medroxyprogesterone | 4 | 1991 | 11 | 0.200 |
Why?
| | Pulse Wave Analysis | 3 | 2023 | 267 | 0.200 |
Why?
| | Chest Pain | 1 | 2024 | 99 | 0.200 |
Why?
| | Muscles | 7 | 1994 | 330 | 0.190 |
Why?
| | Lung Diseases | 3 | 2019 | 780 | 0.190 |
Why?
| | Iliac Artery | 2 | 2014 | 55 | 0.190 |
Why?
| | Polyhydroxyethyl Methacrylate | 1 | 2002 | 10 | 0.190 |
Why?
| | Minority Groups | 2 | 2022 | 284 | 0.190 |
Why?
| | Financing, Organized | 2 | 2020 | 36 | 0.190 |
Why?
| | Financial Management | 1 | 2022 | 16 | 0.190 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2002 | 73 | 0.180 |
Why?
| | Glucose Intolerance | 1 | 2024 | 142 | 0.180 |
Why?
| | Vitamin E | 1 | 2003 | 125 | 0.180 |
Why?
| | Case-Control Studies | 8 | 2025 | 3623 | 0.180 |
Why?
| | Orthopedics | 1 | 2024 | 173 | 0.170 |
Why?
| | Estrogens, Conjugated (USP) | 3 | 1991 | 52 | 0.170 |
Why?
| | Organizational Innovation | 2 | 2020 | 119 | 0.170 |
Why?
| | Congresses as Topic | 2 | 2020 | 223 | 0.170 |
Why?
| | Endovascular Procedures | 2 | 2018 | 390 | 0.170 |
Why?
| | Arginine | 1 | 2003 | 264 | 0.170 |
Why?
| | Placebos | 3 | 2019 | 193 | 0.170 |
Why?
| | Ascorbic Acid | 1 | 2003 | 184 | 0.170 |
Why?
| | Academic Medical Centers | 3 | 2020 | 554 | 0.170 |
Why?
| | Adiponectin | 2 | 2016 | 241 | 0.170 |
Why?
| | Severity of Illness Index | 4 | 2009 | 2930 | 0.160 |
Why?
| | Sulfonylurea Compounds | 2 | 2019 | 51 | 0.160 |
Why?
| | Interdisciplinary Communication | 2 | 2020 | 200 | 0.160 |
Why?
| | Echocardiography, Doppler | 3 | 2016 | 115 | 0.160 |
Why?
| | Sex Distribution | 2 | 2020 | 387 | 0.160 |
Why?
| | Cross-Sectional Studies | 9 | 2025 | 5905 | 0.160 |
Why?
| | Neovascularization, Physiologic | 2 | 2012 | 192 | 0.160 |
Why?
| | Qualitative Research | 3 | 2024 | 1674 | 0.160 |
Why?
| | Cardiovascular Agents | 2 | 2014 | 166 | 0.160 |
Why?
| | Precision Medicine | 2 | 2024 | 459 | 0.150 |
Why?
| | Patient Compliance | 4 | 2015 | 587 | 0.150 |
Why?
| | Time Factors | 11 | 2018 | 7123 | 0.150 |
Why?
| | Arteries | 3 | 2016 | 261 | 0.150 |
Why?
| | Forearm | 2 | 2015 | 141 | 0.150 |
Why?
| | Hemodynamics | 6 | 2009 | 1118 | 0.150 |
Why?
| | Clinical Trials as Topic | 6 | 2019 | 1061 | 0.150 |
Why?
| | Body Composition | 5 | 2014 | 693 | 0.140 |
Why?
| | Pediatric Obesity | 2 | 2017 | 638 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2006 | 1747 | 0.140 |
Why?
| | Telerehabilitation | 1 | 2019 | 47 | 0.140 |
Why?
| | Body Mass Index | 9 | 2017 | 2445 | 0.140 |
Why?
| | Adolescent | 12 | 2022 | 22530 | 0.140 |
Why?
| | Cause of Death | 1 | 2020 | 470 | 0.130 |
Why?
| | Women's Rights | 1 | 2017 | 4 | 0.130 |
Why?
| | Diabetes Complications | 4 | 2010 | 224 | 0.130 |
Why?
| | Leadership | 2 | 2020 | 401 | 0.130 |
Why?
| | Pentoxifylline | 3 | 2006 | 23 | 0.130 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2024 | 627 | 0.130 |
Why?
| | Health Status Indicators | 4 | 2015 | 167 | 0.130 |
Why?
| | Burnout, Professional | 1 | 2024 | 488 | 0.130 |
Why?
| | Program Development | 1 | 2019 | 368 | 0.130 |
Why?
| | Resistance Training | 1 | 2020 | 186 | 0.130 |
Why?
| | Sexism | 1 | 2018 | 68 | 0.130 |
Why?
| | Heart Diseases | 2 | 2019 | 341 | 0.130 |
Why?
| | Aged, 80 and over | 9 | 2012 | 8333 | 0.120 |
Why?
| | Death, Sudden, Cardiac | 1 | 2018 | 232 | 0.120 |
Why?
| | Colorado | 9 | 2017 | 4554 | 0.120 |
Why?
| | Interviews as Topic | 4 | 2024 | 910 | 0.120 |
Why?
| | Ankle Brachial Index | 2 | 2014 | 41 | 0.120 |
Why?
| | Circadian Rhythm | 2 | 2020 | 512 | 0.120 |
Why?
| | Capillaries | 3 | 2012 | 125 | 0.120 |
Why?
| | Microvessels | 1 | 2017 | 97 | 0.120 |
Why?
| | Glucose Tolerance Test | 4 | 2024 | 360 | 0.120 |
Why?
| | Blood Vessels | 1 | 2017 | 167 | 0.120 |
Why?
| | Faculty | 1 | 2017 | 147 | 0.110 |
Why?
| | Reference Values | 4 | 2007 | 798 | 0.110 |
Why?
| | Ischemia | 1 | 2019 | 422 | 0.110 |
Why?
| | Leptin | 1 | 2017 | 248 | 0.110 |
Why?
| | Plethysmography | 3 | 2011 | 104 | 0.110 |
Why?
| | Adiposity | 2 | 2017 | 532 | 0.110 |
Why?
| | Practice Guidelines as Topic | 3 | 2019 | 1581 | 0.110 |
Why?
| | Intention to Treat Analysis | 1 | 2015 | 79 | 0.110 |
Why?
| | Program Evaluation | 2 | 2020 | 943 | 0.110 |
Why?
| | Needs Assessment | 1 | 2018 | 402 | 0.110 |
Why?
| | Myocardium | 1 | 2020 | 934 | 0.110 |
Why?
| | Ventricular Function | 1 | 2015 | 53 | 0.110 |
Why?
| | Health Status Disparities | 1 | 2018 | 321 | 0.110 |
Why?
| | Cardiac Output | 1 | 2015 | 179 | 0.110 |
Why?
| | Physical Education and Training | 1 | 1994 | 70 | 0.110 |
Why?
| | Endothelium | 1 | 2015 | 119 | 0.100 |
Why?
| | Arterial Pressure | 1 | 2015 | 134 | 0.100 |
Why?
| | Healthy Volunteers | 1 | 2015 | 219 | 0.100 |
Why?
| | Oxidative Stress | 1 | 2021 | 1356 | 0.100 |
Why?
| | Pilot Projects | 2 | 2015 | 1891 | 0.100 |
Why?
| | Peripheral Nervous System Diseases | 1 | 1995 | 134 | 0.100 |
Why?
| | Hyperlipidemias | 3 | 2004 | 120 | 0.100 |
Why?
| | Patient Selection | 4 | 2019 | 738 | 0.100 |
Why?
| | Diagnostic Self Evaluation | 1 | 2013 | 23 | 0.100 |
Why?
| | Health Care Costs | 2 | 2014 | 425 | 0.100 |
Why?
| | Angioplasty | 2 | 2009 | 50 | 0.100 |
Why?
| | Aortic Diseases | 1 | 2014 | 125 | 0.100 |
Why?
| | Hypoxia | 3 | 1990 | 1199 | 0.100 |
Why?
| | Menopause | 3 | 1991 | 326 | 0.100 |
Why?
| | Diet, Reducing | 1 | 2013 | 91 | 0.090 |
Why?
| | Reaction Time | 1 | 2015 | 433 | 0.090 |
Why?
| | Carnitine | 5 | 2001 | 91 | 0.090 |
Why?
| | Smoking | 6 | 2010 | 1472 | 0.090 |
Why?
| | Capacity Building | 1 | 2012 | 62 | 0.090 |
Why?
| | Diabetic Nephropathies | 2 | 2014 | 322 | 0.090 |
Why?
| | Premenopause | 2 | 2003 | 125 | 0.090 |
Why?
| | Students, Medical | 1 | 2017 | 378 | 0.090 |
Why?
| | Counseling | 1 | 2015 | 400 | 0.090 |
Why?
| | Heart Ventricles | 1 | 2016 | 756 | 0.090 |
Why?
| | Myocardial Revascularization | 1 | 2011 | 85 | 0.090 |
Why?
| | Kidney | 2 | 2021 | 1497 | 0.080 |
Why?
| | Linear Models | 2 | 2014 | 845 | 0.080 |
Why?
| | Research Report | 1 | 2011 | 86 | 0.080 |
Why?
| | Consensus | 3 | 2019 | 477 | 0.080 |
Why?
| | Clinical Protocols | 1 | 1993 | 280 | 0.080 |
Why?
| | Retrospective Studies | 4 | 2024 | 17291 | 0.080 |
Why?
| | Benchmarking | 1 | 2012 | 191 | 0.080 |
Why?
| | Health Promotion | 1 | 2017 | 775 | 0.080 |
Why?
| | Fatty Acids, Nonesterified | 2 | 2009 | 154 | 0.080 |
Why?
| | Sickness Impact Profile | 1 | 2011 | 62 | 0.080 |
Why?
| | Comorbidity | 4 | 2021 | 1661 | 0.080 |
Why?
| | Hyperemia | 1 | 2011 | 49 | 0.080 |
Why?
| | Self Concept | 1 | 2012 | 253 | 0.080 |
Why?
| | Hemoglobins | 2 | 2017 | 386 | 0.080 |
Why?
| | Coronary Disease | 4 | 2004 | 381 | 0.080 |
Why?
| | Atherosclerosis | 2 | 2011 | 409 | 0.080 |
Why?
| | Niacin | 1 | 2010 | 16 | 0.080 |
Why?
| | Lovastatin | 1 | 2010 | 37 | 0.080 |
Why?
| | Hypertrophy, Left Ventricular | 2 | 2009 | 124 | 0.080 |
Why?
| | Affect | 1 | 2012 | 320 | 0.080 |
Why?
| | C-Reactive Protein | 2 | 2009 | 422 | 0.080 |
Why?
| | Young Adult | 6 | 2024 | 14219 | 0.070 |
Why?
| | Body Fat Distribution | 1 | 2009 | 46 | 0.070 |
Why?
| | Gonadal Steroid Hormones | 1 | 1990 | 143 | 0.070 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2012 | 552 | 0.070 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2002 | 499 | 0.070 |
Why?
| | Heart Function Tests | 1 | 2009 | 59 | 0.070 |
Why?
| | Hyperinsulinism | 2 | 2010 | 114 | 0.070 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2009 | 66 | 0.070 |
Why?
| | Thinness | 1 | 2009 | 100 | 0.070 |
Why?
| | Analysis of Variance | 4 | 2012 | 1300 | 0.070 |
Why?
| | Aorta | 1 | 2011 | 440 | 0.070 |
Why?
| | Fasting | 2 | 2005 | 279 | 0.070 |
Why?
| | Psychometrics | 1 | 2012 | 731 | 0.070 |
Why?
| | Age Factors | 4 | 2021 | 3342 | 0.070 |
Why?
| | Heart Failure | 3 | 2018 | 2326 | 0.070 |
Why?
| | Hospitalization | 1 | 2018 | 2460 | 0.070 |
Why?
| | Puberty | 1 | 2009 | 137 | 0.070 |
Why?
| | Myoglobin | 1 | 2007 | 12 | 0.070 |
Why?
| | Perfusion | 1 | 2009 | 251 | 0.070 |
Why?
| | Angina Pectoris | 1 | 2008 | 76 | 0.070 |
Why?
| | Cost-Benefit Analysis | 4 | 2014 | 639 | 0.070 |
Why?
| | Leisure Activities | 2 | 2006 | 30 | 0.060 |
Why?
| | Mitochondria | 1 | 2014 | 992 | 0.060 |
Why?
| | Inflammation | 3 | 2009 | 2878 | 0.060 |
Why?
| | Awareness | 1 | 2008 | 110 | 0.060 |
Why?
| | Aging | 1 | 2018 | 1969 | 0.060 |
Why?
| | Regression Analysis | 5 | 1998 | 1001 | 0.060 |
Why?
| | Prospective Studies | 8 | 2019 | 8057 | 0.060 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2008 | 1419 | 0.060 |
Why?
| | Prevalence | 3 | 2019 | 2865 | 0.060 |
Why?
| | Dyspnea | 1 | 2008 | 250 | 0.060 |
Why?
| | Chronic Disease | 2 | 2023 | 1808 | 0.060 |
Why?
| | Blood Viscosity | 2 | 1995 | 19 | 0.060 |
Why?
| | Glycation End Products, Advanced | 1 | 2006 | 81 | 0.060 |
Why?
| | Metformin | 2 | 2010 | 329 | 0.060 |
Why?
| | Pulmonary Circulation | 1 | 2007 | 430 | 0.060 |
Why?
| | Glucose Clamp Technique | 1 | 2005 | 199 | 0.060 |
Why?
| | Hematocrit | 2 | 1995 | 108 | 0.050 |
Why?
| | Interleukin-6 | 1 | 2009 | 776 | 0.050 |
Why?
| | Sulfonic Acids | 1 | 2004 | 14 | 0.050 |
Why?
| | Guilt | 1 | 2024 | 10 | 0.050 |
Why?
| | Multicenter Studies as Topic | 2 | 2004 | 412 | 0.050 |
Why?
| | Neoplasms | 2 | 2010 | 2906 | 0.050 |
Why?
| | Nutrition Surveys | 1 | 2006 | 279 | 0.050 |
Why?
| | Animals | 5 | 2018 | 38030 | 0.050 |
Why?
| | Population Dynamics | 1 | 1985 | 142 | 0.050 |
Why?
| | Acetates | 1 | 2004 | 78 | 0.050 |
Why?
| | Work-Life Balance | 1 | 2024 | 22 | 0.050 |
Why?
| | Estrogens | 2 | 2010 | 367 | 0.050 |
Why?
| | Lipids | 1 | 2009 | 707 | 0.050 |
Why?
| | Health Maintenance Organizations | 1 | 2004 | 105 | 0.050 |
Why?
| | Biopsy | 3 | 2012 | 1082 | 0.050 |
Why?
| | Incidence | 3 | 2019 | 2923 | 0.050 |
Why?
| | Cohort Studies | 3 | 2016 | 6013 | 0.050 |
Why?
| | Dietary Carbohydrates | 1 | 2004 | 147 | 0.050 |
Why?
| | Body Weight | 2 | 2006 | 971 | 0.050 |
Why?
| | Mitochondrial Diseases | 1 | 2024 | 92 | 0.050 |
Why?
| | Physicians, Women | 1 | 2024 | 89 | 0.050 |
Why?
| | Intracranial Arterial Diseases | 1 | 2002 | 8 | 0.050 |
Why?
| | Genetic Vectors | 1 | 2004 | 335 | 0.050 |
Why?
| | Dietary Fats | 1 | 2004 | 308 | 0.050 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 286 | 0.050 |
Why?
| | Child | 5 | 2017 | 22707 | 0.050 |
Why?
| | Serum Globulins | 1 | 2002 | 5 | 0.050 |
Why?
| | Glycolysis | 1 | 2024 | 340 | 0.050 |
Why?
| | Musculoskeletal Diseases | 1 | 2003 | 90 | 0.040 |
Why?
| | Genetic Therapy | 1 | 2004 | 316 | 0.040 |
Why?
| | Psychomotor Performance | 1 | 2004 | 324 | 0.040 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2002 | 85 | 0.040 |
Why?
| | Prognosis | 2 | 2010 | 4316 | 0.040 |
Why?
| | Lung | 1 | 2015 | 4106 | 0.040 |
Why?
| | Single-Blind Method | 2 | 2013 | 318 | 0.040 |
Why?
| | Pelvis | 1 | 2002 | 125 | 0.040 |
Why?
| | Proteinuria | 1 | 2001 | 104 | 0.040 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2001 | 94 | 0.040 |
Why?
| | Diet | 2 | 2010 | 1277 | 0.040 |
Why?
| | Homocysteine | 1 | 2002 | 152 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2005 | 645 | 0.040 |
Why?
| | Physical Examination | 1 | 2002 | 243 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 820 | 0.040 |
Why?
| | Alcohol Drinking | 2 | 2010 | 837 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2002 | 171 | 0.040 |
Why?
| | Ambulatory Care | 2 | 2014 | 609 | 0.040 |
Why?
| | Patient Satisfaction | 2 | 2002 | 709 | 0.040 |
Why?
| | Fibrinogen | 1 | 2002 | 180 | 0.040 |
Why?
| | Altitude | 1 | 1985 | 463 | 0.040 |
Why?
| | Multivariate Analysis | 3 | 2014 | 1547 | 0.040 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2000 | 30 | 0.040 |
Why?
| | Aorta, Thoracic | 1 | 2023 | 286 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 229 | 0.040 |
Why?
| | Cholesterol, LDL | 2 | 2014 | 360 | 0.040 |
Why?
| | Administration, Oral | 1 | 2003 | 866 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2004 | 728 | 0.040 |
Why?
| | Tissue Plasminogen Activator | 1 | 2002 | 248 | 0.040 |
Why?
| | Myocardial Ischemia | 1 | 2002 | 285 | 0.040 |
Why?
| | Medroxyprogesterone Acetate | 2 | 1990 | 33 | 0.040 |
Why?
| | Organization and Administration | 1 | 2019 | 14 | 0.040 |
Why?
| | Specialties, Surgical | 1 | 2000 | 82 | 0.040 |
Why?
| | Internal Medicine | 1 | 2002 | 279 | 0.040 |
Why?
| | Femoral Artery | 2 | 2011 | 190 | 0.040 |
Why?
| | Pregnancy | 3 | 2020 | 7202 | 0.040 |
Why?
| | Apoptosis | 1 | 2007 | 2440 | 0.040 |
Why?
| | Sports Medicine | 2 | 2010 | 118 | 0.040 |
Why?
| | Asia | 1 | 2018 | 70 | 0.040 |
Why?
| | Risk Adjustment | 1 | 2019 | 85 | 0.040 |
Why?
| | Densitometry | 1 | 1998 | 36 | 0.030 |
Why?
| | Lactic Acid | 2 | 1998 | 295 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2019 | 130 | 0.030 |
Why?
| | Hypercapnia | 2 | 1989 | 53 | 0.030 |
Why?
| | Coronary Vessels | 1 | 2020 | 246 | 0.030 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2001 | 345 | 0.030 |
Why?
| | Rural Population | 2 | 1995 | 659 | 0.030 |
Why?
| | Walking Speed | 1 | 2018 | 53 | 0.030 |
Why?
| | Cell Respiration | 1 | 2018 | 105 | 0.030 |
Why?
| | Autonomic Nervous System | 1 | 1998 | 82 | 0.030 |
Why?
| | Public Health | 1 | 2023 | 572 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2002 | 440 | 0.030 |
Why?
| | Walk Test | 1 | 2018 | 81 | 0.030 |
Why?
| | Secondary Prevention | 1 | 2019 | 251 | 0.030 |
Why?
| | Family Practice | 1 | 2001 | 407 | 0.030 |
Why?
| | Hand Strength | 1 | 2018 | 144 | 0.030 |
Why?
| | Drug Therapy, Combination | 2 | 2010 | 1044 | 0.030 |
Why?
| | Neural Conduction | 2 | 1995 | 92 | 0.030 |
Why?
| | Capillary Resistance | 1 | 2017 | 4 | 0.030 |
Why?
| | Social Stigma | 1 | 2020 | 172 | 0.030 |
Why?
| | Career Choice | 1 | 2019 | 234 | 0.030 |
Why?
| | Oxyhemoglobins | 1 | 2017 | 28 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.030 |
Why?
| | Acute Disease | 1 | 2020 | 1036 | 0.030 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2017 | 133 | 0.030 |
Why?
| | Depression | 1 | 2007 | 1546 | 0.030 |
Why?
| | Caloric Restriction | 1 | 2018 | 133 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2013 | 3413 | 0.030 |
Why?
| | Weight Reduction Programs | 1 | 2018 | 140 | 0.030 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2017 | 70 | 0.030 |
Why?
| | Canada | 1 | 2018 | 431 | 0.030 |
Why?
| | Heart | 1 | 2020 | 626 | 0.030 |
Why?
| | Bicycling | 1 | 2017 | 117 | 0.030 |
Why?
| | Forecasting | 2 | 2000 | 390 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2013 | 1997 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2017 | 370 | 0.030 |
Why?
| | Social Support | 1 | 2020 | 646 | 0.030 |
Why?
| | Matched-Pair Analysis | 1 | 1995 | 37 | 0.030 |
Why?
| | Stroke Volume | 1 | 2018 | 654 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 389 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 383 | 0.030 |
Why?
| | Risk | 1 | 2017 | 919 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2016 | 277 | 0.030 |
Why?
| | Energy Intake | 3 | 2006 | 512 | 0.030 |
Why?
| | Electrophysiology | 1 | 1995 | 218 | 0.030 |
Why?
| | Cystatin C | 1 | 2014 | 66 | 0.030 |
Why?
| | Vascular Patency | 1 | 2014 | 121 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2014 | 123 | 0.030 |
Why?
| | Models, Economic | 1 | 2014 | 61 | 0.030 |
Why?
| | Phosphorus | 1 | 2014 | 90 | 0.030 |
Why?
| | Life Expectancy | 1 | 2014 | 73 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2019 | 777 | 0.030 |
Why?
| | Hospital Costs | 1 | 2014 | 125 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2016 | 494 | 0.030 |
Why?
| | Constriction, Pathologic | 1 | 2014 | 249 | 0.030 |
Why?
| | Databases, Factual | 2 | 2011 | 1490 | 0.020 |
Why?
| | Health Behavior | 1 | 2019 | 789 | 0.020 |
Why?
| | Drug Costs | 1 | 2014 | 117 | 0.020 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2014 | 146 | 0.020 |
Why?
| | Health Education | 1 | 2016 | 346 | 0.020 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2014 | 203 | 0.020 |
Why?
| | Collateral Circulation | 2 | 2003 | 20 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 740 | 0.020 |
Why?
| | Creatinine | 1 | 2014 | 515 | 0.020 |
Why?
| | Administrative Personnel | 1 | 2012 | 33 | 0.020 |
Why?
| | Carotid Stenosis | 1 | 2014 | 107 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2013 | 283 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 857 | 0.020 |
Why?
| | Blood Vessel Prosthesis | 1 | 2013 | 140 | 0.020 |
Why?
| | Waist Circumference | 1 | 2012 | 143 | 0.020 |
Why?
| | Treatment Failure | 1 | 2013 | 360 | 0.020 |
Why?
| | Health Planning | 1 | 1992 | 47 | 0.020 |
Why?
| | North Carolina | 1 | 2012 | 129 | 0.020 |
Why?
| | Internship and Residency | 1 | 2002 | 1267 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1707 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 74 | 0.020 |
Why?
| | Muscle Contraction | 1 | 2014 | 429 | 0.020 |
Why?
| | Muscle Strength | 1 | 2014 | 332 | 0.020 |
Why?
| | Popliteal Artery | 1 | 2011 | 62 | 0.020 |
Why?
| | Cerebrovascular Disorders | 1 | 1992 | 104 | 0.020 |
Why?
| | Estrone | 1 | 1991 | 41 | 0.020 |
Why?
| | Radioimmunoassay | 1 | 1991 | 165 | 0.020 |
Why?
| | Behavior Therapy | 1 | 2014 | 296 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2014 | 765 | 0.020 |
Why?
| | Follicular Phase | 1 | 1990 | 41 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 969 | 0.020 |
Why?
| | Metabolism | 1 | 1990 | 44 | 0.020 |
Why?
| | Luteal Phase | 1 | 1990 | 51 | 0.020 |
Why?
| | C-Peptide | 1 | 1991 | 190 | 0.020 |
Why?
| | Incretins | 1 | 2010 | 21 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2010 | 64 | 0.020 |
Why?
| | Receptor, Insulin | 1 | 2010 | 93 | 0.020 |
Why?
| | Health Services Research | 1 | 2012 | 391 | 0.020 |
Why?
| | Acetylcarnitine | 1 | 1989 | 6 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 560 | 0.020 |
Why?
| | Actigraphy | 1 | 2010 | 148 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 848 | 0.020 |
Why?
| | Progesterone | 1 | 1991 | 215 | 0.020 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2015 | 549 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2010 | 189 | 0.020 |
Why?
| | Risk Assessment | 2 | 2009 | 3747 | 0.020 |
Why?
| | Respiration Disorders | 1 | 1989 | 78 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1193 | 0.020 |
Why?
| | Partial Pressure | 1 | 1988 | 30 | 0.020 |
Why?
| | Energy Metabolism | 3 | 2006 | 935 | 0.020 |
Why?
| | Estradiol | 1 | 1991 | 515 | 0.020 |
Why?
| | Drug Interactions | 1 | 1989 | 405 | 0.020 |
Why?
| | Tidal Volume | 1 | 1988 | 109 | 0.020 |
Why?
| | Pain | 1 | 1993 | 789 | 0.020 |
Why?
| | Ankle Joint | 1 | 2008 | 122 | 0.020 |
Why?
| | Risk Reduction Behavior | 1 | 2009 | 217 | 0.020 |
Why?
| | Fluoroquinolones | 1 | 2007 | 44 | 0.020 |
Why?
| | Caspase 3 | 1 | 2007 | 242 | 0.020 |
Why?
| | Models, Cardiovascular | 1 | 2007 | 196 | 0.020 |
Why?
| | Receptor for Advanced Glycation End Products | 1 | 2006 | 33 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2010 | 379 | 0.010 |
Why?
| | Testosterone | 1 | 2010 | 416 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2014 | 2953 | 0.010 |
Why?
| | Carbon Dioxide | 1 | 1988 | 227 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2007 | 762 | 0.010 |
Why?
| | Income | 1 | 2007 | 202 | 0.010 |
Why?
| | Receptors, Immunologic | 1 | 2006 | 208 | 0.010 |
Why?
| | Sterol O-Acyltransferase | 1 | 2004 | 6 | 0.010 |
Why?
| | Sleep Wake Disorders | 1 | 1989 | 314 | 0.010 |
Why?
| | Acetamides | 1 | 2004 | 41 | 0.010 |
Why?
| | Case Management | 1 | 2004 | 68 | 0.010 |
Why?
| | Age Distribution | 1 | 2004 | 403 | 0.010 |
Why?
| | Cell Adhesion Molecules | 1 | 2004 | 181 | 0.010 |
Why?
| | Calcium-Binding Proteins | 1 | 2004 | 221 | 0.010 |
Why?
| | Gene Transfer Techniques | 1 | 2004 | 187 | 0.010 |
Why?
| | Cognition Disorders | 1 | 2007 | 541 | 0.010 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2004 | 376 | 0.010 |
Why?
| | Cytokines | 1 | 2010 | 2067 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3904 | 0.010 |
Why?
| | Endpoint Determination | 1 | 2001 | 85 | 0.010 |
Why?
| | Lactates | 2 | 1992 | 82 | 0.010 |
Why?
| | Ultrasonography, Doppler | 1 | 2001 | 126 | 0.010 |
Why?
| | World Health Organization | 1 | 2000 | 104 | 0.010 |
Why?
| | Attitude | 1 | 2002 | 259 | 0.010 |
Why?
| | Sulfonamides | 1 | 2004 | 583 | 0.010 |
Why?
| | Wound Healing | 1 | 2003 | 355 | 0.010 |
Why?
| | Algorithms | 1 | 2008 | 1845 | 0.010 |
Why?
| | Costs and Cost Analysis | 1 | 2000 | 221 | 0.010 |
Why?
| | Artificial Limbs | 1 | 2003 | 208 | 0.010 |
Why?
| | Indians, North American | 1 | 2004 | 597 | 0.010 |
Why?
| | Logistic Models | 1 | 2004 | 2134 | 0.010 |
Why?
| | Models, Biological | 1 | 2006 | 1764 | 0.010 |
Why?
| | Interpersonal Relations | 1 | 2002 | 397 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2002 | 1323 | 0.010 |
Why?
| | Models, Theoretical | 1 | 2000 | 558 | 0.010 |
Why?
| | Diabetic Neuropathies | 1 | 1998 | 100 | 0.010 |
Why?
| | Diabetic Retinopathy | 1 | 1998 | 209 | 0.010 |
Why?
| | Muscle Fibers, Skeletal | 1 | 1996 | 212 | 0.010 |
Why?
| | Rehabilitation | 1 | 1992 | 20 | 0.010 |
Why?
| | Cholesterol, HDL | 1 | 1991 | 201 | 0.000 |
Why?
| | Hydroxybutyrates | 1 | 1989 | 15 | 0.000 |
Why?
| | 3-Hydroxybutyric Acid | 1 | 1989 | 17 | 0.000 |
Why?
| | Electromyography | 1 | 1992 | 419 | 0.000 |
Why?
| | Blood Gas Analysis | 1 | 1989 | 81 | 0.000 |
Why?
| | Ultrasonics | 1 | 1989 | 50 | 0.000 |
Why?
| | Nervous System Diseases | 1 | 1992 | 286 | 0.000 |
Why?
| | Action Potentials | 1 | 1992 | 502 | 0.000 |
Why?
| | Sleep Apnea Syndromes | 1 | 1989 | 98 | 0.000 |
Why?
| | Drug Combinations | 1 | 1989 | 396 | 0.000 |
Why?
| | Mice | 1 | 1989 | 18329 | 0.000 |
Why?
|
|
Regensteiner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|